首页 | 本学科首页   官方微博 | 高级检索  
     


A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B‐cell non‐Hodgkin lymphoma: A Wisconsin Oncology Network study
Authors:Timothy S. Fenske MD  Namrata M. Shah MD  Kyung Mann Kim PhD  Sandeep Saha MS  Chong Zhang MS  Arielle E. Baim BA  John P. Farnen MD  Adedayo A. Onitilo MD  Jules H. Blank MD  Harish Ahuja MD  Tim Wassenaar MD  Rubina Qamar MD  Patrick Mansky MD  Anne M. Traynor MD  Ryan J. Mattison MD  Brad S. Kahl MD
Affiliation:1. Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin;2. Department of Biostatistics and Medical Informatics, University of Wisconsin Carbone Cancer Center, Madison, Wisconsin;3. Gundersen Lutheran Health System, La Crosse, Wisconsin;4. Marshfield Clinic, Weston, Wisconsin;5. St. Vincent Regional Cancer Center, Green Bay, Wisconsin;6. Aspirus Regional Cancer Center, Wausau, Wisconsin;7. ProHealth Care Cancer Center, Waukesha, Wisconsin;8. Aurora Cancer Care, Wauwatosa, Wisconsin;9. Bellin Health, Green Bay, Wisconsin;10. Department of Medicine, University of Wisconsin Carbone Cancer Center, Madison, Wisconsin
Abstract:
Keywords:bortezomib  clinical trial  non‐Hodgkin lymphoma  phase 2  temsirolimus
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号